Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer Blue Earth Diagnostics’ Axumin (fluciclovine F-18) positron emission tomography (PET) imaging agent through PETNET’s national network.

Magnetic resonance imaging (MRI) exams before and after space missions reveal that astronauts' brains compress and expand during spaceflight, according to a University of Michigan study.

In humans, the part of the brain that's responsible for face recognition continues to grow into adulthood, according to a new study published in Science. The results are surprising, since brain development is largely thought to involve synaptic pruning, rather than growth. The ability to recognize faces, which is critical for everyday social interactions, improves from childhood to adulthood.

A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending peptide receptor radionuclide therapy targeting the somatostatin receptor to other types of malignancies beyond neuroendocrine tumors (NETs). The theranostic pairing of Netspot (Ga-68 DOTATATE, which is U.S. Food and Drug Administration [FDA]-approved) and Lutathera (Lu-177-DOTATATE, currently under FDA review) has already shown that it can significantly improve progression-free survival in patients with somatostatin receptor-positive NETs.